PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50124C00010Development of a NOVEL pralidoxime chloride — Kaleo, Inc

Kaleo, Inc holds $33.3M across 3 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Oct 31, 2028 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Kaleo, Inc

Recipient

Oct 31, 2028

PoP end

$33.3M

Obligated

541714

NAICS

AN42

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

NONE

Contract number75A50124C00010

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

IncumbentKaleo, Inc

UEILBM4GLJNDK31

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAN42

Place of performanceRICHMOND, VA

Related solicitationBAA-23-100-SOL-00004

PoP end (current)Oct 31, 2028

Obligated$33.3M

DEVELOPMENT OF A NOVEL PRALIDOXIME CHLORIDE AUTO-INJECTOR DEVICE is a federal NONE award for Barda - Aspr / Daappo / Barda Dcma held by Kaleo, Inc. Estimated value $33.3M ($33.3M obligated). Current period of performance ends Oct 31, 2028. Last award drew 1 bidder. Place of performance: RICHMOND, VA. Related solicitation BAA-23-100-SOL-00004.

DEVELOPMENT OF A NOVEL PRALIDOXIME CHLORIDE AUTO-INJECTOR DEVICE

Recompete timing

Public

● Expiring in 765 days

Current PoP ends Oct 31, 2028 (765 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around May 1, 2027.

Bonuses end Sept 30

Want the durability read on 75A50124C00010? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Kaleo, Inc — $33.3M obligated across 3 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$33.3M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50124C00010?

75A50124C00010 (Development of a NOVEL pralidoxime chloride) is a Barda - Aspr / Daappo / Barda Dcma award with an estimated value of $33.3M, currently held by Kaleo, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50124C00010?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50124C00010 to Kaleo, Inc.

Who is the incumbent on 75A50124C00010?

Kaleo, Inc is the incumbent with $33.3M across 3 related awards in SCOUT’s public footprint. The current period of performance ends Oct 31, 2028.

When does Kaleo, Inc’s 75A50124C00010 come up for recompete?

SCOUT tracks a period-of-performance end of Oct 31, 2028. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 75A50124C00010? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 20, 2026 · refreshed monthlyLatest procurement action May 27, 2026